A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
1234 details |
| Primary information | |
|---|---|
| ThPP ID | Th1032 |
| Therapeutic Peptide/Protein Name | Coagulation factor VIIa |
| Sequence | ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta |
| Functional Classification | Ib |
| Molecular Weight | 45079.1 |
| Chemical Formula | C1972H3076N560O597S28 |
| Isoelectric Point | 6.09 |
| Hydrophobicity | -0.311 |
| Melting Point (℃) | 58 |
| Half Life | N.A. |
| Description | Recombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form. |
| Indication/Disease | For treatment of hemorrhagic complications in hemophilia A and B. |
| Pharmacodynamics | To treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting. |
| Mechanism of Action | NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin. |
| Toxicity | N.A. |
| Metabolism | N.A. |
| Absorption | N.A. |
| Volume of Distribution | 121 ± 30 mL/kg [adults] |
| Clearance | 33 - 37 mL/h x kg [healthy] |
| Categories | Coagulants |
| Patents Number | N.A. |
| Date of Issue | N.A. |
| Date of Expiry | N.A. |
| Drug Interaction | Autoplex T (anti-inhibitor coagulant complex) |
| Target | Coagulation factor X,Serine protease hepsin,Tissue factor pathway inhibitor,Vitamin K-dependent gamma-carboxylase,Coagulation factor VII,Tissue factor |
| Information of corresponding available drug in the market | |
| Brand Name | NovoSeven |
| Company | Novo Nordisk |
| Brand Discription | NovoSeven is recombinant human coagulation Factor VIIa, intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven (coagulation factor viia recombinant) is a vitamin K-dependent glycoprotein consisting of 4 |
| Prescribed for | For treatment and prevention of bleeding in surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response |
| Chemical Name | N.A. |
| Formulation | Each vial contains approximately 0. 6 mg/mL NovoSeven (coagulation factor viia recombinant) (corresponding to 600 _g/mL). The reconstituted vials have a pH of approximately 5. 5 in sodium chloride (3 mg/mL), calcium chloride dihydrate (1. 5 mg/mL), glycyl |
| Physcial Appearnce | Sterile, white lyophilized powder |
| Route of Administration | Injection |
| Recommended Dosage | For bleeding episodes, the recommended dose of NovoSeven (coagulation factor viia (recombinant)) for hemophilia A or B patients with inhibitors is 90 _g/kg given every two hours by bolus infusion until hemostasis is achieved, or until thehemostasis has been acheived. |
| Contraindication | Hypersensitivity |
| Side Effects | Rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; bleeding at the injection site; bloody stools; calf or stomach pain, tenderness, or swelling; chest pain; confusion; dizziness; fainting; numbness. |
| Useful Link | http://www.novosevenrt.com |
| PubMed ID | 16418464 |
| 3-D Structure | Th1032 (View) or (Download) |